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Abstract: The reported work demonstrates and discusses the effect of supercritical fluid density 
(pressure and temperature of supercritical fluid carbon dioxide) on particle size and distribution 
using the supercritical antisolvent (SAS) method in the purpose of drug encapsulation. In this 
study, paracetamol was encapsulated inside L-polylactic acid, a semicrystalline polymer, 
with different process parameters, including pressure and temperature, using the SAS 
process. The morphology and particle size of the prepared nanoparticles were determined by 
scanning electron microscopy and transmission electron microscopy. The results revealed that 
increasing temperature enhanced mean particle size due to the plasticizing effect. Furthermore, 
increasing pressure enhanced molecular interaction and solubility; thus, particle size was reduced. 
Transmission electron microscopy images defined the internal structure of nanoparticles. Thermal 
characteristics of nanoparticles were also investigated via differential scanning calorimetry. 
Furthermore, X-ray diffraction pattern revealed the changes in crystallinity structure during 
the SAS process. In vitro drug release analysis determined the sustained release of paracetamol 
in over 4 weeks.
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Introduction
The use of supercritical fluid (SCF) is an effective and clean method in the production 
of encapsulated particles. The pressure and temperature of SCF are greater than 
its critical pressure and temperature while it remains as a single phase. The SCF 
  techniques modify the particle size, distribution, and morphology. The major advantage 
of supercritical antisolvent (SAS) techniques is that the solvent can be efficiently 
removed. Furthermore, it is a single-step process and a clean and effective method for 
nanoencapsulation, and the mild operation temperature avoids thermal degradation. 
Supercritical solvation power can be readily controlled by adjusting either temperature 
or pressure; thus, it can be used for selective crystallization and control of particle 
morphology or crystalline forms.1–3
The conventional processes for encapsulation such as milling, solvent evaporation 
and spray drying cannot produce fine and pure particles. Particles that are produced 
by milling method have a large distribution range. Solvent/emulsion evaporation 
techniques cannot completely remove solvent from the particles, and the spray drying 
process can thermally denaturate compounds.4
During the SAS processes, the mass transfer between SCF and solution happens 
very quickly because of very high diffusion of SCF in the solution, which results in 
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the expansion of solution. Therefore, the solubility power 
is decreased, and a supersaturated solution results in 
precipitation.
The density of SCF affects mass transfer between 
organic solvent and SCF during precipitation. The density 
of SCF depends on the temperature and pressure values of 
the fluid.5–8 This work has studied the effect of temperature 
and pressure on particle size and distribution produced by 
the SAS process.
SAS precipitation description should include important 
contributions from precipitation kinetics, thermodynamics, 
and fluid dynamics. Furthermore, study of phase behavior 
is key in this area.
Materials and methods
Poly-L-lactic acid used in this study (inherent viscosity 
2.0 dL/g, as reported by the supplier), as the biodegradable 
polymer, was obtained from Sigma-Aldrich (St, Louis, MO). 
Paracetamol (99.9%) was obtained from the Faculty of 
Medicine and Health Science, UPM, Malaysia. Methylene 
chloride  (purity  99.8%)  high-performance  liquid 
chromatography grade, as solvent for biodegradable 
polymer, was obtained from Sigma-Aldrich. Acetone (purity 
99.8%) high-performance liquid chromatography grade, as 
solvent for paracetamol, was obtained from Fisher Scientific 
(Loughborough, UK). Purified grade carbon dioxide (CO2) 
was used as the SCF.
Preparation of nanoparticles
The SAS apparatus consisted of a high-pressure pump 
(Thar SCF P-50A) and a metering pump (Chrom Tec Series 
III) used to deliver the supercritical CO2 and feed solution, 
respectively. During the SAS process, supercritical CO2 fluid 
diffused and evaporated in the gas phase. Therefore, the 
density of the solvent decreased and precipitation occurred. 
The very fast mass transfer between the liquid phase and SCF 
reduced the surface tension and controlled droplet shape. 
A stainless steel cylindrical vessel of 490 mL was used as 
a precipitation chamber. The liquid solution (composed of 
poly-L-lactic acid and paracetamol [2:1] dissolved in the 
mixture solvent of dichloromethane and acetone [7:4]) 
was delivered to the precipitation chamber with a constant 
flow rate equal to 1.75 mL/minute through a 2 µm diameter 
stainless steel nozzle. A chiller (Thermo Scientific) and a 
heat exchanger were used to liquify CO2 from a gas cylinder 
when the chiller temperature dropped to 3°C and the CO2 
was delivered through another inlet port located on the top 
of the precipitator. The temperature of precipitation chamber 
was controlled using a water bath in the varied range equal 
to 30°C, 35°C, 40°C, 45°C, 50°C, and 55°C. The pressure 
of the precipitator was regulated by a micrometering valve 
located at the exit of the chamber in the varied range equal to 
80 bar, 90 bar, 100 bar, 110 bar, and 120 bar. The produced 
particles were collected in the precipitator chamber. The SAS 
apparatus is shown in Figure 1.
Observation and characterization
Scanning electron microscopy
Scanning electron microscopy (SEM) (Hitachi S-3400 N) 
was used to characterize the morphology and particle size 
of the nanoencapsulated particles. The sample was adhered 
to the adhesive carbon tape on an aluminum stub and coated 
with gold-palladium. The morphology of the samples was 
characterized using SEM, and images were taken from a 
variety of areas of the samples on the stub. Particle size and 
their distributions were determined using the UTHSCSA 
Image Tool software, Version 3.00 program, based on the 
SEM micrographs. More than 500 particles from each sample 
were taken for image processing.
Transmission electron microscopy
Transmission electron microscopy (TEM) (LEO 912AB) was 
used to characterize the internal structure of nanoencapsu-
lated particles. One drop of sample was placed on a copper 
grid and dried. Then, the copper grid was scanned with TEM 
for investigation of the internal structure.
Energy dispersive X-ray spectroscopy
Element compositions were investigated using a NORAN 
SYSTEM 6.0 (Thermo Scientific). It was followed with an 
acquisition time of approximately 5 minutes at 20 KV .
Figure 1 Equipment set-up used in this study for supercritical antisolvent system.
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Figure 2 Scanning electron microscopy micrographs of nanoencapsulated paracetamol inside L-polylactic acid at 120 bar and different temperatures: (A) 30°C, (B) 35°C, 
(C) 40°C, D) 45°C, (E) 50°C, (F) 55°C.
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Figure 3 Effect of temperature on particle size.
Differential scanning calorimetry
A weighted sample more than 5 mg was collected in 
an   aluminum pan (Al-Crucibles 40 µL) and sealed 
  completely. The system was purged with nitrogen (gas 
control Ts0800GC1) to prevent oxidation or other undesired 
  reactions. The analysis of samples was performed in the 
temperature range of 0°C–200°C at the rate of 2°C/min.
X-ray diffraction pattern
The X-ray diffractograms were recorded by Shimadzo 
XRD-6000 equipment with Ni-filtered Cu-Kα radiation. 
The operating conditions were 20 mA and 40 KV at room 
temperature. The X-ray diffractograms were recorded with 
the scan rate of 4 s/step and step width 0.05°.
In vitro drug release
A total of 25 mg of nanoparticles was placed into 50 mL of 
phosphate buffered saline (PBS) (pH 7.4) containing 0.025% 
sodium azide. The sample was placed in a shaking incubator 
maintained at 50 rpm and 37°C. The paracetamol released 
into the medium PBS was analyzed using an ultraviolet-
visible spectrometer (Shimadzu Model 1650-PC, Japan).
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
2167
Supercritical antisolvent methodInternational Journal of Nanomedicine 2012:7
Results and discussion
Particle size, morphology, and internal 
structure of nanoparticles
SEM micrographs of products produced in the temperature 
below 45°C show fine spherical particles with all different 
pressures. By increasing the temperature and thus 
decreasing the density, the particle size increases due to 
the plasticizing effect. Supercritical CO2 decreases the 
glass transition temperature of biodegradable polymers, 
acting like a plasticizer. Therefore, the polymer with a 
low glass transition temperature tends to form sticky and 
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Figure 4 Scanning electron microscopy micrographs of nanoencapsulated paracetamol inside L-polylactic acid at 30ºC and different pressures: (A) 80 bar, (B) 90 bar,   
(C) 100 bar, (D) 110 bar (E) 120 bar.
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Figure 5 Effect of pressure on particle size.
aggregated particles.9,10 At temperatures higher than 45°C, 
which is near the glass transition temperature of polymers, 
the particles are agglomerated, and large and nonspherical 
particles are formed.11 The glass transition temperature of 
some polymers may be decreased after contact with SCF 
due to taking the place of CO2 for a very short time because 
of intermolecular interaction between the biodegradable 
polymer and dissolved SCF.12 The effect of temperature 
on particle size and their morphology at 120 bar is shown 
in Figure 2. The same results occur with other pressures 
(Figure 3).
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In order to control the washing step, energy   dispersive 
X-ray spectroscopy characterization was carried out 
(Figure 7). During the observation with SEM, the electron 
beams were directed toward the sample and emitted X-rays 
were examined. The position of X-ray peaks reveals the ele-
ments available in the sample. No peaks related to chlorine 
arising from Di-chloromethan (methylene chloride) solvent 
in the spectrum of sample were detected. Therefore, the 
methylene chloride solvent was completely removed from 
products during the washing step.
Structure of nanoparticles
Based on the diffraction patterns, it is distinguished that the 
based peak of nanoparticle crystallographs are equal to pure 
polymer (16.64°) due to the higher ratio of polymer over par-
acetamol in the initial solute (Figure 8). Furthermore, the crys-
tallinity structure changes during the SAS process due to the 
very fast mass transfer during the SAS process and produces 
particles that precipitate very quickly. Therefore, there is not 
sufficient time to produce particles in the crystal structure. The 
change in crystallinity is observed on both the X-ray diffrac-
tion pattern (Figure 8) and differential scanning calorimetry 
(DSC) thermograms (Figure 9). The intensity of crystallinity 
peaks of nanoencapsulated particles obviously reduced in 
DSC thermograms. Based on the surface area of exothermal 
Figure 6 Internal structure of nanoparticles.
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Figure  7  Energy  dispersive  X-ray  spectroscopy  of  nanoparticles  revealed  the 
completed washing step.
Also, the particles size is reduced through   pressure 
enhancement. In fact, the solubility of solute in the 
supercritical CO2 depends on the density. Density increment 
enhances the molecular interaction and thus the solubility. 
The effect of density on solubility is more considerable at 
higher densities.13
SEM micrographs of products in different pressures at 
30°C are shown in Figure 4. The same results occur with 
other pressures (Figure 5).
Other important factors in respect of particle size are 
nucleation process and rapid mass transfer of antisolvent 
and solvent leading to high supersaturations for the solute, 
which results in rapid nucleation and growth of more than 
one particle per primary droplet.13,14
The TEM images revealed the encapsulation of 
paracetamol inside biodegradable polymer, as shown in 
Figure 6.
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Figure  8  X-ray  diffraction  pattern  of  pure  L-polylactic  acid  (L-PLA),  pure 
paracetamol, and encapsulated paracetamol inside L-PLA.
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peak and endothermal peak, the percentage of crystallinity in 
this polymer can be distinguished. In the   crystalline phase of 
polymer, the atoms are arranged   regularly; thus, it absorbed 
a huge energy to break the crystalline   structure, but during 
the melting process the energy was released. The degree of 
crystallinity is obtained as follows:
  ∆∆
∆
Hm Hc
Hm
−
×=
0
100 Percentageof crystallinity   (1)
where ∆Hm is the enthalpy of fusion and is determined 
by the area integration of the melting peak (71.18 J/gr), 
∆Hc is the heat of crystallinity and is determined by the 
area integration of the crystallinity peak (30.24 J/gr), and 
∆Hm0 is the enthalpy of fusion of the completely crystalline 
  material or corresponds to an infinite thickness of crystal 
equal to 81.3 J/gr. The crystallinity of pure polymer is equal 
to 50.35% based on the DSC thermogram.
In vitro drug release analysis
Sustained release of paracetamol in PBS buffer was 
investigated over 4 weeks. The first burst happened after 
1 week and the cumulative paracetamol release versus time 
is shown in Figure 10. The kinetic of releasing is fitted with a 
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Figure 10 In vitro release profile of paracetamol encapsulated in L-polylactic acid based on the zero-order model.
57.96oC
92.2oC
181.733oC
171.9oC
171.833oC
Pure LPLA   
Encapsulated drug at 100 bar, 45
OC
Encapsulated drug at 120 bar, 30
OC
−60 −40 −20 20 40 60 80 100 120 140 160 180 200 0
Figure 9 The comparison of melting point and crystallinity of pure L-polylactic acid and nanoparticles produced in different conditions.
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zero-order model based on R-square (92.2%). The zero-order 
kinetic model Eq (2), shows that the drug release rate is 
independent of its concentration:15
  C = K.t  (2)
where K is zero-order rate constant expressed and t is 
the time.
Conclusion
The antisolvent SCF process is a suitable process for 
  pharmaceutical application, and it is possible to control the 
particle size and its distribution and the shapes and structure 
of   particles in a wide range by adjusting the process parameter 
and choosing a suitable biodegradable polymer.16 For the SAS 
process the ternary system is shown in Figure 11.
According to this diagram, φ1 is the one-phase region in 
which the biodegradable polymer dissolves in the solvent. 
In this region, CO2 may also dissolve in the solution.   
The φ2 region shows the glassy region, which is a polymer-
rich phase. In this region the limited amount of solvent and 
CO2 makes a solution with polymer. In the two-phase regions 
(φ1+ φ2), both a solvent-rich phase and a polymer-rich phase 
exist and are in equilibrium. The curve line from point C to 
point B shows the polymer solubility in both solvent and 
SCFs. The polymer solute feeding to SCF is shown with 
a straight line. By adding the solution to supercritical CO2 
fluid (ScCO2), the small amount of the solute dissolves in 
the ScCO2 (in φ1 region); the process continues until the 
saturation point of the solute in the mixture of the solvent 
and ScCO2, the supersaturation point, is reached. Finally, by 
adding more solute into the SCF, the supersaturation and then 
the phase transition will take place.
The process conditions during solute spraying can 
change the properties of biodegradable polymer such as 
viscosity; thus, the precipitation occurs. It is crucial that 
the precipitation rate be lower than the atomization rate to 
produce desirable particle sizes and morphology. In addi-
tion, the biodegradable polymer must precipitate during 
spraying due to avoiding polymeric droplet production 
and agglomeration.13,17 Increasing the density enhances the 
molecular interaction and thus the solubility, and this effect is 
even more sensitive at higher densities. To sum up, this study 
realized that increasing pressure and decreasing temperature 
can improve particle size and morphology. Furthermore, it 
is distinguished that crystallinity structure changes during 
the SAS process. The nanoparticles showed very slow drug 
release in a buffer solution.
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